Related Experiment Video
Updated: Jun 28, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
AR-V7 expression facilitates accelerated G2/M phase transition in castration-resistant prostate cancer
Taruna Saini1, Parth Gupta1, Rajnikant Raut1
1Department of Biotechnology, Indian Institute of Technology Hyderabad, Kandi, Sangareddy, 502284, India.
Abstract:
The emergence of AR-V7, a truncated isoform of AR upon androgen deprivation therapy treatment, leads to the development of castration resistant prostate cancer (CRPC). Understanding mechanisms that regulate AR-V7 expression is critical for developing newer therapeutic strategies. In this study, we have investigated the regulation of AR-V7 during cell cycle and identified a distinct pattern of periodic fluctuation, peaking during G2/M phase. This fluctuation correlates with the expression of Cdc-2 like kinase 1 (CLK1) and phosphorylated serine/arginine-rich splicing factor 1 (p-SRSF1) during these phases, pointing towards their role in AR-V7 generation. Functional assays reveal that CLK1 knockdown prolongs the S phase, leading to altered cell cycle distribution and increased accumulation of AR-V7 and pSRSF1 in G1/S phase. Conversely, CLK1 overexpression rescues AR-V7 and p-SRSF1 levels in the G2/M phase, consistent with observed cell cycle alterations upon AR-V7 knockdown and overexpression in CRPC cells. Furthermore, overexpression of kinase-deficient CLK1 mutant leads to diminished AR-V7 levels during G2/M, underlining the essential contribution of CLK1's kinase activity in modulating AR-V7 expression. Collectively, our findings, for the first time, show periodic regulation of AR-V7 expression, its effect on cell cycle progression and the critical role of CLK1-pSRSF1 axis in modulating AR-V7 expression throughout the cell cycle.
Insights
Androgen receptor variant 7 (AR-V7) expression fluctuates during the cell cycle, peaking in G2/M phase. The CLK1-pSRSF1 pathway critically regulates AR-V7 generation in castration resistant prostate cancer.
Area of Science:
- Oncology
- Molecular Biology
- Cell Biology
Background:
- Androgen deprivation therapy (ADT) resistance in prostate cancer is often driven by the emergence of the AR-V7 splice variant.
- Understanding the regulation of AR-V7 is crucial for developing effective therapeutic strategies against castration resistant prostate cancer (CRPC).
Purpose of the Study:
- To investigate the cell cycle-dependent regulation of AR-V7 expression.
- To identify key molecular players involved in AR-V7 generation during the cell cycle.
Main Methods:
- Cell cycle analysis using flow cytometry.
- Western blotting to detect protein levels of AR-V7, CLK1, and p-SRSF1.
- Knockdown and overexpression experiments of CLK1 in CRPC cells.
Main Results:
- AR-V7 expression exhibits periodic fluctuations, peaking during the G2/M phase of the cell cycle.
- CLK1 and phosphorylated SRSF1 (p-SRSF1) expression correlate with AR-V7 levels during specific cell cycle phases.
- CLK1 activity is essential for modulating AR-V7 levels, with kinase-deficient mutants reducing AR-V7 expression.
Conclusions:
- AR-V7 expression is periodically regulated throughout the cell cycle.
- The CLK1-pSRSF1 axis plays a critical role in the generation of AR-V7.
- Targeting CLK1 activity may offer a novel therapeutic approach for CRPC by modulating AR-V7 expression.
Related Concept Videos
Negative Regulator Molecules
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Abnormal Proliferation
The Ras Gene
Ras is a...

